Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
RXST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.32 - $57.53
Previous CloseN/A
Volume110.15K
Average Volume (3M)1.19M
Market Cap
$347.79M
Enterprise Value$313.89M
Total Cash (Recent Filing)$227.49M
Total Debt (Recent Filing)$11.71M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Nov 06, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding40,915,962
10 Day Avg. Volume1,323,898
30 Day Avg. Volume1,186,713
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue2.00
Enterprise Value/Gross Profit2.92
Enterprise Value/Ebitda-8.90
Forecast
1Y Price Target
$8.86Price Target Upside3.63% Upside
Rating ConsensusHold
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Commercial StrategyRXST is focusing on increasing utilization through surgeon training and practice support, which is expected to boost adoption.
Competitive AdvantageRXST has a strong first-mover advantage in the light adjustable lenses market, having captured about 10% of the advanced technology intraocular lens market since its launch.
Market OpportunityInternational markets represent a significant opportunity for RXST, with plans to enter European and Asian markets where the advanced technology IOL market is twice the size of the US market.
Bears Say
Financial PerformanceRXST reported revenue of $33.6M, which was below initial consensus estimates and BTIG's estimate.
Market CompetitionCompetition and consumer confidence are risks as other companies are launching competing AT-IOLs in the US, potentially impacting RXST’s growth.
Revenue GuidanceRXST cut 2025 revenue guidance by 25% after cutting it 12% in Q1.
RxSight News
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $6.32 and its highest was $57.53 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $347.79M.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on Aug 07, 2025. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.254 by -$0.036.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.37.
How many shares outstanding does RxSight have?
RxSight has 40,915,962 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.254. Following the earnings report the stock price went down -7.702%.
Which hedge fund is a major shareholder of RxSight?
Currently, no hedge funds are holding shares in RXST
RxSight Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.86 (3.63% Upside)
$8.86 (3.63% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 760.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.88%
12-Months-Change
Fundamentals
Return on Equity
-11.66%
Trailing 12-Months
Asset Growth
1.15%
Trailing 12-Months
Company Description
RxSight
RxSight, Inc. (RXST) operates in the healthcare sector, focusing on ophthalmic innovations. The company is known for its development and commercialization of the Light Adjustable Lens (LAL), a breakthrough in cataract surgery that allows for postoperative vision adjustments to improve patient outcomes. RxSight is committed to enhancing vision care through advanced technology and improving the quality of life for patients undergoing cataract surgeries.
RXST Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted positive aspects such as increased LAL revenue, improved gross margin, and international market expansion. However, significant challenges were noted including overall revenue decline, decreased LDD sales, increased net loss, and higher operating expenses. The guidance for a revenue decline further contributed to the cautious outlook.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$8.86
▲(3.63% Upside)
Technical Analysis
Ownership Overview
5.57% Insiders
16.77% Mutual Funds
35.92% Other Institutional Investors
25.04% Public Companies and
Individual Investors